CDK4/6 inhibitors have been proposed for use in combination therapy with a CDK2 inhibitor to prevent compensatory upregulation of CDK4/6 activity, allowing cancer cells to bypass the G1/S checkpoint (48). Here, CDK4 is linked to cancer.